Andrew James King - Net Worth and Insider Trading

Andrew James King Net Worth

The estimated net worth of Andrew James King is at least $773,751 dollars as of 2024-05-13. Andrew James King is the Chief Scientific Officer of Chinook Therapeutics Inc and owns about 19,157 shares of Chinook Therapeutics Inc (KDNY) stock worth over $773,751. Details can be seen in Andrew James King's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Andrew James King has not made any transactions after 2023-08-01 and currently still holds the listed stock(s).

Transaction Summary of Andrew James King

To

Andrew James King Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Andrew James King owns 2 companies in total, including Aduro Biotech Inc (ADRO) , and Chinook Therapeutics Inc (KDNY) .

Click here to see the complete history of Andrew James King’s form 4 insider trades.

Insider Ownership Summary of Andrew James King

Ticker Comapny Transaction Date Type of Owner
ADRO Aduro Biotech Inc 2020-10-05 Head of Renal Discovery
KDNY Chinook Therapeutics Inc 2023-08-01 Head of Renal Discovery

Andrew James King Latest Holdings Summary

Andrew James King currently owns a total of 1 stock. Andrew James King owns 19,157 shares of Chinook Therapeutics Inc (KDNY) as of August 1, 2023, with a value of $773,751.

Latest Holdings of Andrew James King

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
KDNY Chinook Therapeutics Inc 2023-08-01 19,157 40.39 773,751

Holding Weightings of Andrew James King


Andrew James King Form 4 Trading Tracker

According to the SEC Form 4 filings, Andrew James King has made a total of 13 transactions in Chinook Therapeutics Inc (KDNY) over the past 5 years, including 0 buys and 13 sells. The most-recent trade in Chinook Therapeutics Inc is the sale of 1,168 shares on August 1, 2023, which brought Andrew James King around $45,587.

Insider Trading History of Andrew James King

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Andrew James King Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Andrew James King Ownership Network

Ownership Network List of Andrew James King

No Data

Ownership Network Relation of Andrew James King


Andrew James King Owned Company Details

What does Aduro Biotech Inc do?

Who are the key executives at Aduro Biotech Inc?

Andrew James King is the Head of Renal Discovery of Aduro Biotech Inc. Other key executives at Aduro Biotech Inc include director & President & CEO Eric Dobmeier , 10 percent owner Versant Voyageurs I, L.p. , and 10 percent owner Versant Voyageurs I Parallel, L.p. .

Aduro Biotech Inc (ADRO) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Aduro Biotech Inc (ADRO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aduro Biotech Inc (ADRO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Aduro Biotech Inc (ADRO)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Aduro Biotech Inc Insider Transactions

No Available Data

Andrew James King Mailing Address

Above is the net worth, insider trading, and ownership report for Andrew James King. You might contact Andrew James King via mailing address: C/o Chinook Therapeutics U.s., Inc., 1600 Fairview Ave. E., Seattle Wa 98102.

Discussions on Andrew James King

No discussions yet.